BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37340812)

  • 1. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
    Wang TF; Grubic N; Carrier M; Canney M; Delluc A; Hundemer GL; Knoll G; Lazo-Langner A; Massicotte-Azarniouch D; Tanuseputro P; Sood MM
    Am J Hematol; 2023 Sep; 98(9):1374-1382. PubMed ID: 37340812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty.
    Simon SJ; Patell R; Zwicker JI; Kazi DS; Hollenbeck BL
    JAMA Netw Open; 2023 Dec; 6(12):e2345883. PubMed ID: 38039005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
    Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
    Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
    Lazo-Langner A; Fleet JL; McArthur E; Garg AX
    J Thromb Haemost; 2014 Oct; 12(10):1626-35. PubMed ID: 25069387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
    J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
    Feng W; Wang X; Huang D; Lu A
    Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
    Suen K; Westh RN; Churilov L; Hardidge AJ
    J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin.
    Hovik O; Amlie EJ; Jenssen KK
    J Arthroplasty; 2021 Oct; 36(10):3589-3592. PubMed ID: 34176693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.
    Arsoy D; Giori NJ; Woolson ST
    Clin Orthop Relat Res; 2018 Feb; 476(2):381-387. PubMed ID: 29529673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
    Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
    JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin Versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review.
    Chua CXK; Tan JHI; Bin Abd Razak HR
    J Arthroplasty; 2022 Mar; 37(3):593-600.e1. PubMed ID: 34843908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.